Literature DB >> 8861737

The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics.

A A Piergies1, J Sweet, M Johnson, B F Roth-Schechter, S Allard.   

Abstract

Since early treatment of depression with Selective Serotonin Reuptake Inhibitor (SSRI) can be associated with insomnia, daytime antidepressive therapy with SSRI is often combined with nighttime administration of a hypnotic. This study attempted to evaluate the pharmacokinetic and pharmacodynamic interactions between zolpidem 10 mg, a short-acting hypnotic, and fluoxetine 20 mg, an SSRI. Twenty-seven healthy male volunteers (mean age 23.5 years, range 20 - 29) received zolpidem and fluoxetine in the following open design: zolpidem on night 1, a morning dose of fluoxetine daily from day 2 through day 18 and zolpidem on night 18. Using HPLC, plasma levels of zolpidem, fluoxetine, and norfluoxetine were determined throughout night 1 for zolpidem, night 18 for zolpidem, fluoxetine, and norfluoxetine on days 16 and 17 for fluoxetine and norfluoxetine. Morning psychomotor tests were performed on days 1, 2, 18, and 19. Statistical analysis of data consisted of repeated measures of ANOVA. There was no significant difference in AUC, C(max), and T1/2 of zolpidem plasma concentrations between night 1 (zolpidem) and night 18 (zolpidem and fluoxetine). There was a significantly higher zolpidem plasma level at 0.5 hours after dosing together with a significantly shorter T(max) on night 18 compared to night 1. There was no significant difference in C(min) of plasma fluoxetine and norfluoxetine levels between day 16 and 17 of fluoxetine dosing, and there was no difference in T(max) between day 17 (fluoxetine) and day 18 (fluoxetine and zolpidem). There was a 3 - 4% increase in AUC and C(max) of fluoxetine and norfluoxetine plasma concentrations in the presence of zolpidem. There was no difference in the next morning performance tests after nighttime treatment of zolpidem alone after 17 consecutive days of fluoxetine treatment, or after zolpidem in the presence of steady-state plasma concentrations of fluoxetine. Both zolpidem and fluoxetine were well tolerated alone or in combination. It is concluded that the onset of action of zolpidem may possibly be shortened in the presence of fluoxetine, but no other significant pharmacokinetic or pharmacodynamic interactions occurred between zolpidem and fluoxetine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861737

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  10 in total

1.  Initiation of illusions after combination of zolpidem and paroxetine in a young woman: a case report.

Authors:  Demetris Skourides; Lampros Samartzis
Journal:  Prim Care Companion CNS Disord       Date:  2012-07-19

Review 2.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations.

Authors:  L L Von Moltke; D J Greenblatt; B W Granda; S X Duan; J M Grassi; K Venkatakrishnan; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 4.  Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem.

Authors:  G Chouinard; K Lefko-Singh; E Teboul
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 5.  New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.

Authors:  Mario Giovanni Terzano; Mariano Rossi; Vincenzo Palomba; Arianna Smerieri; Liborio Parrino
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 6.  Sublingual zolpidem (Edluar™; Sublinox™).

Authors:  Lily P H Yang; Emma D Deeks
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 7.  Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Authors:  Leah M Hesse; Lisa L von Moltke; David J Greenblatt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

8.  Zolpidem : Forensic aspects for the toxicologist and pathologist.

Authors:  Timothy P Rohrig; Christine M Moore
Journal:  Forensic Sci Med Pathol       Date:  2005-06       Impact factor: 2.456

9.  Case report: Chronological symptom profile after cessation of overdose zolpidem in a patient with comorbid bipolar disorder-from anxiety, craving, paresthesia and influenza-like symptoms to seizures and hallucinations.

Authors:  Zi-Xin Mao; Xia Yang; Hui-Yao Wang; Wan-Jun Guo
Journal:  Front Psychiatry       Date:  2022-08-17       Impact factor: 5.435

10.  Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate.

Authors:  Thomas Roth; David Mayleben; Bruce C Corser; Nikhilesh N Singh
Journal:  Hum Psychopharmacol       Date:  2008-01       Impact factor: 1.672

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.